Stephen D Schmidt
Overview
Explore the profile of Stephen D Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
16558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Cheng C, Dal Santo J, Shen C, Bylund T, Henry A, et al.
Cell
. 2024 Oct;
187(25):7214-7231.e23.
PMID: 39471811
An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection...
2.
Dias J, Fabozzi G, Fourati S, Chen X, Liu C, Ambrozak D, et al.
Nat Commun
. 2024 Aug;
15(1):7461.
PMID: 39198422
Anti-HIV-1 broadly neutralizing antibodies (bNAbs) have the dual potential of mediating virus neutralization and antiviral effector functions through their Fab and Fc domains, respectively. So far, bNAbs with enhanced Fc...
3.
Pegu A, Lovelace S, DeMouth M, Cully M, Morris D, Li Y, et al.
Sci Transl Med
. 2024 Jan;
16(730):eadh9039.
PMID: 38232141
The fusion peptide (FP) on the HIV-1 envelope (Env) trimer can be targeted by broadly neutralizing antibodies (bNAbs). Here, we evaluated the ability of a human FP-directed bNAb, VRC34.01, along...
4.
Lima N, Musayev M, Johnston T, Wagner D, Henry A, Wang L, et al.
Nat Commun
. 2022 Dec;
13(1):7733.
PMID: 36517467
An important consequence of infection with a SARS-CoV-2 variant is protective humoral immunity against other variants. However, the basis for such cross-protection at the molecular level is incompletely understood. Here,...
5.
Zhang B, Gollapudi D, Gorman J, ODell S, Damron L, McKee K, et al.
Sci Rep
. 2022 Oct;
12(1):17876.
PMID: 36284200
The broadly neutralizing antibody (bNAb) CAP256-VRC26.25 has exceptional potency against HIV-1 and has been considered for clinical use. During the characterization and production of this bNAb, we observed several unusual...
6.
Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Liang C, et al.
Nat Med
. 2022 Oct;
29(1):247-257.
PMID: 36265510
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) vaccine efficacy and persistent transmission. In this...
7.
Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Jani H, et al.
bioRxiv
. 2022 Oct;
PMID: 36263060
The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and...
8.
Gagne M, Moliva J, Foulds K, Andrew S, Flynn B, Werner A, et al.
Cell
. 2022 Apr;
185(9):1556-1571.e18.
PMID: 35447072
SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman...
9.
Lima N, Musayev M, Johnston T, Wagner D, Henry A, Wang L, et al.
bioRxiv
. 2022 Apr;
PMID: 35378757
An important consequence of infection with a SARS-CoV-2 variant is protective humoral immunity against other variants. The basis for such cross-protection at the molecular level is incompletely understood. Here we...
10.
DeGrace M, Ghedin E, Frieman M, Krammer F, Grifoni A, Alisoltani A, et al.
Nature
. 2022 Apr;
605(7911):640-652.
PMID: 35361968
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused...